Compare MRAM & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | PALI |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.3M | 240.2M |
| IPO Year | 2016 | 2019 |
| Metric | MRAM | PALI |
|---|---|---|
| Price | $9.75 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $14.00 | $12.00 |
| AVG Volume (30 Days) | 270.2K | ★ 4.0M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,417,000.00 | $260,000.00 |
| Revenue This Year | $10.22 | N/A |
| Revenue Next Year | $7.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 37.51 | ★ 1500.39 |
| 52 Week Low | $4.68 | $0.55 |
| 52 Week High | $17.24 | $2.64 |
| Indicator | MRAM | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 49.78 |
| Support Level | $8.40 | $1.57 |
| Resistance Level | $9.81 | $2.05 |
| Average True Range (ATR) | 0.54 | 0.18 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 88.55 | 58.09 |
Everspin Technologies Inc is a manufacturer of Magnetoresistive Random Access Memory (MRAM) technology. The company manufactures MRAM products using both captive and third-party manufacturing capabilities. It purchases industry-standard complementary metal-oxide semiconductor (CMOS) wafers from semiconductor foundries and perform back end of line (BEOL) processing that includes magnetic-bit technology at leased 200mm fabrication facility in Chandler, Arizona. It also manufactures full-flow 300mm CMOS wafers with STT-MRAM magnetic-bit technology integrated in BEOL. The company's customers are in key markets, such as industrial, medical, automotive/transportation, aerospace, and data center.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.